CytRx Corporation (CYTR) Reaches Enrollment Target in International Phase 2b Clinical Trial With Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma
6/24/2013 9:29:13 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that it has reached the targeted enrollment of 105 evaluable patients in its international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for soft tissue sarcoma. This trial allows for a head-to-head clinical comparison of the efficacy and safety of the commonly used chemotherapeutic agent doxorubicin with aldoxorubicin, CytRx’s improved version of doxorubicin.
Help employers find you! Check out all the jobs and post your resume.
comments powered by